[Form 4] Corcept Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) – Form 4 insider transaction

CEO & Director Joseph K. Belanoff reported selling a total of 40,000 common shares on 01-Aug-2025 under a pre-arranged Rule 10b5-1 plan adopted 26-Nov-2024. The disposals occurred in three blocks at weighted-average prices of $67.8063, $68.8689 and $69.6483.

After the sales, Belanoff’s revocable living trust holds 2,861,370 shares of CORT, over which he retains voting power but disclaims full beneficial ownership except for his pecuniary interest. No derivative securities were exercised or affected, and no corporate financial data or guidance accompanied the filing.

Insights

Securities Analyst

TL;DR: 40k-share CEO sale; neutral sentiment given 10b5-1 plan and substantial remaining stake.

The Form 4 shows routine disposition by Corcept’s long-tenured CEO. While insider selling can raise eyebrows, the transaction is covered by a pre-scheduled 10b5-1 plan and represents roughly 1.4% of his indirect holdings, leaving a sizeable 2.86 million-share position. There are no red flags such as option exercises or sudden bulk liquidation. Given the absence of accompanying operational news, the market impact should be modest.

Corporate Governance Specialist

TL;DR: Governance-compliant sale; low investor risk.

The filing demonstrates good governance: advance adoption of a 10b5-1 plan, clear disclosure of price ranges, and affirmation of voting agreements. The remaining stake maintains alignment between management and shareholders. Therefore, the event is classified as routine and not materially impactful to the investment thesis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BELANOFF JOSEPH K

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		S(1)		16,745	D	$67.8063(2)	2,884,625	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)
Common Stock	08/01/2025		S(1)		17,809	D	$68.8689(4)	2,866,816	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)
Common Stock	08/01/2025		S(1)		5,446	D	$69.6483(5)	2,861,370	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $67.42 to $68.33 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $68.43 to $69.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.4412 to $69.77 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff.	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.